NUVB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Nuvation Bio Inc. (NUVB) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company has strong positive catalysts, including expanded clinical trials, increasing analyst price targets, and a significant revenue increase. While insider selling and negative short-term stock trends are concerns, the long-term growth potential and positive sentiment outweigh these factors.
The MACD is positive and expanding (0.0781), indicating bullish momentum. RSI is neutral at 61.008, and moving averages are converging, suggesting consolidation. The stock is trading near its pivot level (5.676), with resistance at 5.955 and support at 5.397.
Expansion of the SIGMA study to Phase 3 for high-risk IDH1-mutant astrocytoma patients.
Analyst upgrades with higher price targets ($13, $12, $
and Buy/Outperform ratings.
Revenue growth of 1704.68% YoY in Q3
Diversified oncology strategy with promising clinical-stage candidates.
Insider selling increased by 287.18% over the last month.
Short-term stock trend suggests minor declines in the next day (-0.05%), week (-0.26%), and month (-1.9%).
Gross margin dropped significantly (-168.71% YoY).
In Q3 2025, revenue increased by 1704.68% YoY to $13.12M. Net income improved by 35.38% YoY but remains negative at -$55.79M. EPS increased by 6.67% YoY to -0.16. However, gross margin dropped significantly to 74.47%.
Analysts are optimistic, with multiple upgrades in price targets (ranging from $10 to $18) and Buy/Outperform ratings. Analysts highlight the strong uptake of the Ibtrozi franchise and the company's diversified oncology pipeline as key strengths.
